A South Korea-based digital health company, HolmesAI, has unveiled a new artificial intelligence-driven wearable platform designed to bring advanced cardiac risk monitoring into the home.
The system combines continuous electrocardiogram (ECG) data from wearable sensors with machine learning analytics to detect a wide range of heart rhythm abnormalities and estimate short-term risk of cardiac arrest in real time.
The platform integrates with consumer-grade wearable devices such as smartwatches and utilises AI models trained to recognise patterns associated with more than 20 distinct types of cardiac arrhythmias. By continuously analysing ECG signals and other physiological inputs, the system can identify irregular heart rhythms that might otherwise go unnoticed between clinical visits. This capability aims to support early intervention for conditions such as atrial fibrillation and other rhythm disturbances that are known contributors to stroke, heart failure and sudden cardiac events.
A distinguishing feature of the new platform is its predictive analytics component. Rather than simply recording and classifying rhythm abnormalities after they occur, the AI assesses temporal changes in cardiac signals and related metrics to generate risk estimates for cardiac arrest within a defined short-term window. This function is intended to provide actionable insights that can prompt timely medical review or emergency response before a critical event unfolds.
Healthcare technology trends underscore a broader shift toward continuous remote monitoring and preventive care, moving beyond episodic evaluations in clinics or hospitals. Wearable ECG and AI-based diagnostic tools have been studied for their ability to improve early detection of arrhythmias like atrial fibrillation, which has been shown in other research to be caught more frequently with wearable monitoring compared with traditional screening alone.
This move by HolmesAI reflects a growing interest among startups and medical technology companies in leveraging real-world physiological data through wearables paired with intelligent analytics to support decentralised cardiovascular care. Similar advances in cardiac monitoring technology have appeared in recent years, including FDA-cleared ECG devices that enable arrhythmia assessment outside of traditional clinical settings and other AI-enhanced wearable systems aimed at expanding access to continuous heart health insights.
By enabling users to track heart rhythm anomalies and near-term risk indicators from their daily environments, the new platform could play a role in expanding access to preventive cardiac care, especially for individuals with known risk factors or existing cardiovascular disease.
Also Read